Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin

Guillermo Cabrera Álvarez, Diana Lizbeth Gómez-Galicia, Lourdes Rodríguez‐Fragoso, Vicente Madrid Marina, Luis Cañedo Dorantes, Miguel Ángel Sánchez-Alemán, Nahúm Méndez‐Sánchez, Jorge Reyes‐Esparza
In: Annals of Hepatology · 2011 · vol. 10(4) , pp. 458–468 · doi:10.1016/s1665-2681(19)31513-3 · PMID:21911886 · W5061555
article OA: hybrid CC0 ⤵ 3 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Danazol administered alongside peginterferon and ribavirin increased platelet counts in HCV patients, maintaining platelet levels in most patients and correlating with improved liver function and sustained viral response.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV. OBJECTIVE: The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF and ribavirin treatment in patients with HCV. MATERIAL AND METHODS: We included patients whose platelets were < 90,000/mm³ and who were undergoing antiviral treatment. Danazol (300-600 mg/day) was administered during and until the end of antiviral therapy [7.6 months (2 to 11 months)]. The monitoring was performed through platelet analysis and liver function tests. A viral load test was done at the beginning and end of treatment. Fortynine patients receiving a combined therapy of PEG-INF, ribavirin and Danazol increased their platelet levels to 121,081/mm³ (46,000-216,000/mm³); 10.6% of patients gained > 100,000 platelets/mm³, and 71% of patients maintained their initial platelet levels. Sustained viral response (SVR) was achieved in 63% of patients. SVR rates were high in patients with genotype non 1 (78.7%) and decreased in patients with genotype 1 (60.1%). The increase in platelet levels was associated to an increase in fibrinogen levels and a decrease in the activity of ALT. By contrast, patients without SVR presented a delayed response to increased platelet levels and showed no significant improvement in liver function when they received Danazol. CONCLUSION: Danazol can be used along with PEG-INF and ribavirin to treat thrombocytopenia in patients with HCV.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (3)

References (40)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-10T10:40:48.377557+00:00
License: CC0 · commercial use OK